British Journal of Haematology · 1994 · 37 citations · 15 references
MedicineHematologyChemotherapyHematologic OncologyHematopathologyBone Marrow EvaluationBone Marrow PathologyChemotherapy In Hematologic MalignanciesClinical HematologyHematologic MalignanciesPlatelet PhysiologyBone Marrow AssessmentCoagulationEarly Recurrence PredictionHematologic Malignancy ManagementLeukemia Marrow AssessmentNegativityPlatelet Count MonitoringSensitivity
We report the results of serial tests in three patients with hyperleucocytotic AML M3 by haematological methods, coagulation assays and PCR analyses following treatment with ATRA and chemotherapy. All three patients became PCR negative in bone marrow and peripheral blood (sensitivity level 1 in 10(5) cells) after one cycle of ATRA + chemotherapy. However, they relapsed haematologically 6-9 months after achieving complete haematological remission. The haematological relapse was preceded by PCR positivity in the bone marrow by 3 months. Platelet counts decreased already during CHR, but dropped below normal levels only at the time of relapse. Coagulation parameters were not helpful for early prediction of relapse. Our results demonstrate that PCR analysis in the bone marrow is the best way to monitor patients with APL. However, in hyperleucocytotic patients, PCR negativity does not seem to indicate long-term remission.
15
Raymond P. Warrell · New England Journal of Medicine · 1993 · 795 citations
Medicine, Hematology, Pharmacology +16
Reassessing the hemostatic disorder associated with acute promyelocytic leukemia [see comments]
MS Tallman, H.C. Kwaan · Blood · 1992 · 297 citations · Full text
Medicine, Hematology, Oncology +12